Introduction
============

Australia and New Zealand, followed by North America, were the countries with the highest prostate cancer incidence in the developed world in 2012, according to the World Health Organization ([@B25]). In 2016, 18,138 males were diagnosed with prostate cancer in Australia, accounting for 25.2% of all new male cancer cases and 12.8% of all male deaths caused by cancer ([@B57]). In an increasing aging population, the numbers of newly diagnosed men with prostate cancer are likely to rise. Despite all the accumulated knowledge of the disease, the prostate-specific antigen (PSA) test remains one of the most common methods of screening since its introduction 30 years ago. However, the PSA test has gathered criticism for its potential over-diagnosis ([@B15]) and overtreatment consequences ([@B23]). In 2012, The American Society of Clinical Oncology ([@B4]) and the U.S. Preventive Services Task Force ([@B34]) recommended against its use as a routine screening test. In this light, new and more specific biomarkers are needed.

Microsatellites, or short tandem repeats (STRs), are typically consecutive repeats of 2--5 base pairs (bp) of DNA in the genome. STRs are attractive biomarkers in human disease due to their highly polymorphic nature, abundancy, and wide distribution throughout the genome ([@B43]; [@B59]). They have been used for high-resolution human genome mapping ([@B26]), population studies ([@B13]; [@B10]), and associated with up to 40 human monogenic diseases such as oculopharyngeal muscular dystrophy ([@B59]), as well as with more complex diseases such as cystic fibrosis and asthma ([@B22]; [@B7]).

Genome-Wide Association Studies (GWAS) genotype large cohorts of patients and controls, using high-throughput screening platforms to identify single-nucleotide polymorphisms (SNPs) that are associated with prostate cancer. This approach has been successful in identifying over 150 susceptibility loci for prostate cancer in a European cohort ([@B2]; [@B47]; [@B44]). However, GWAS conducted to date can explain only up to ∼33% of prostate cancer heredity ([@B2]). We hypothesize that some of the missing prostate cancer genetic component can be explained by other genetic variants such as STRs. We used existing expression databases and bioinformatics tools that detect functional STRs lying in differentially expressed genes in prostate cancer as described previously by us ([@B27]), whereby we identified a penta-STR within the 3′UTR of the tribbles homologue 1 gene (*TRIB1*): TTTTG-*TRIB1*. Recent studies have associated the *TRIB1* gene with the development of several tumors including colorectal ([@B54]), leukemia ([@B63]), and hepatocellular ([@B61]) cancers. Also, in prostate cancer it has recently shown to have a role in cancer cell proliferation, survival and tumor growth ([@B32]). Furthermore, independent clinical studies have reported higher expression of *TRIB1* in prostate cancer when compared to other cancers ([@B49]; [@B38]) and an up-regulation of the *TRIB1* gene in prostate cancer tissue when compared to adjacent cancer-free cells ([@B30]; [@B18]). However, the mechanisms by which its expression is upregulated in prostate cancer are not yet understood ([@B64]; [@B51]; [@B18]; [@B32]). Additionally, we and others have observed a down-regulation of the TTTTG-*TRIB1* STR and the *TRIB1* gene ([@B35]; [@B27]) in LNCaP cells after androgen treatment, supporting a link between *TRIB1* and prostate cancer. Interestingly, a recent study has observed an increase of *TRIB1* DNA copies and mRNA levels in breast cancer patients with a poorer survival outcome and a more aggressive phenotype in ([@B17]) after regulating proliferation, apoptosis, and cytokine production. Here, we undertook the largest genotyping analysis of a microsatellite repeat in this gene and analyzed its association with prostate cancer risk, aggressiveness and survival.

Materials and Methods {#s1}
=====================

*TRIB1* Expression in Cancer
----------------------------

The Oncomine gene mining database ([@B40]) was used to determine how the *TRIB1* gene expression in prostate cancer compares with other cancers (**Figures [1A,B](#F1){ref-type="fig"}**) and to confirm if its expression was higher in prostate tumor tissue when compared to non-tumor prostatic tissue (**Figures [1C,D](#F1){ref-type="fig"}**). This mining web-tool extracts differential gene expression data from microarray analysis which originate from numerous samples such as cancer physiological fluids and tissues. Clinical and pathological data is also made available to the user. All the data presented is normalized and statistically analyzed.

![*TRIB1* is overexpressed in prostatate cancer. The Oncomine database showed that *TRIB1* was overexpressed in **(A)** prostate cancer when compared to eight (*n* = 174; [@B49]), **(B)** and four other cancer types (*n* = 76; [@B38]) and in prostate cancer when compared to adjacent cancer-free tissue with in **(C)** [@B18] dataset (*n* = 122) and **(D)** [@B30] dataset (*n* = 57); BlCa, bladder cancer; BCa, breast cancer; CoCa, colorectal cancer; KiCa, kidney cancer; LiCa, liver cancer; LuCa, lung cancer; OvCa, ovarian cancer; PaCa, pancreatic cancer; PCa, prostate cancer.](fgene-09-00428-g001){#F1}

In order to analyze the expression of the *TRIB1* gene in multiple cancer types, two multi-cancer studies were selected. The selection criteria were based on their number of samples and data availability for the prostate cancer. In the first study (**Figure [1A](#F1){ref-type="fig"}**) by [@B49] *TRIB1* gene expression data was available from prostate tumor as well as eight other cancers (*n* = 174; bladder, breast, colorectal, kidney, liver, lung, ovarian, and pancreatic). In the second study (**Figure [1B](#F1){ref-type="fig"}**), [@B38] analyzed the *TRIB1* gene expression in prostate malignant tissue and compared it to four other cancer types (*n* = 76; breast, colorectal, lung and ovarian). The arrays used in the first study were the Human Genome U95A-Av2 Array while the HumanGeneFL Array, Hu35KsubA Array was used in the second study.

We then searched for reported differential expression of the *TRIB1* gene in prostate cancer when compared to prostatic benign tissue. Two studies that reflect this differential expression were selected for their number of samples available. The first study selected was carried out by [@B18]; **Figure [1C](#F1){ref-type="fig"}**), where a total of 122 samples were analyzed (59 localized prostate carcinoma, and 28 benign prostate tissue specimens) using the Agilent Human Genome 44K array. The second selected study was presented by [@B29]; **Figure [1D](#F1){ref-type="fig"}**), where a total of 57 samples (44 prostate carcinoma and 13 adjacent normal samples) using the Human Genome U133A Array.

Prostate Cancer Patients and Cancer-Free Controls
-------------------------------------------------

A total of 1,152 prostate patients were analyzed, including 138 men recruited via collaborations with urologists, 347 men from the QLD node of the Australian Prostate Cancer BioResource (APCB) and 667 men recruited in collaboration with the Cancer Council Queensland ProsCan study as detailed in our previous studies ([@B5]; [@B31]; [@B14]).

An extensive medical record for each patient that includes parameters such as age at diagnosis, family history of prostate cancer, ethnicity, PSA levels and survival data were collected, as well as pathology reports, including Gleason scores. Survival data was obtained through Cancer registry, which is maintained by Cancer Council Queensland (last extraction-2016). The registry operates under an Act of Parliament that requires mandatory notification of all cancer cases in Queensland by all hospitals (public, private, and psychiatric), nursing homes, and pathology laboratories. Death certificates are accessed to identify if the cause of death is cancer.

A total of 1,196 cancer-free control participants were included in the study. None of the controls included had been diagnosed with prostate cancer at the time of collection or presented any symptoms. From these, 527 men recruited through the Electoral Roll were age- and postal code-matched to patients from the ProsCan study. A further 669 male controls were recruited through the Australian Red Cross Blood Services. All cancer-free volunteers completed a detailed questionnaire that included information such as age, height and weight at the time of recruitment, and it also included risk factors and sociodemographic variables like family history of prostate cancer, whether they have had a vasectomy, as well as epidemiological factors such as, smoking, drinking and education. The scale used for all the variables are summarized in **Table [1](#T1){ref-type="table"}**. All cases and controls were of European ancestry. This study was approved by the Queensland University of Technology's Human Ethics Committee (Ethics' Approval Number: 1000001171), and all participants provided informed written consent to participate in prostate cancer genetic studies.

###### 

Socio-demographic and clinical characteristics of the Queensland study populations.

  Characteristics                                         Men with prostate cancer (*n* = 1152) *n* (%)   Healthy controls (*n* = 1196) *n* (%)   *P-*values
  ------------------------------------------------------- ----------------------------------------------- --------------------------------------- ------------------
  Age in years (mean, range)                              63.1 (40.2--87.1)                               60.3 (18--89.6)                         *P* \< 0.0001^c^
  BMI (mean, SD)                                          28.4 (4.7)                                      27.9 (4.5)                              *P* = 0.091^c^
  **Marital status**                                                                                                                              
  Never married                                           14 (1)                                          8 (1)                                   
  Married/de facto                                        423 (37)                                        113 (9)                                 
  Divorced/separated/widowed                              44 (4)                                          13 (1)                                  *P* \> 0.9^c^
  Unknown                                                 672 (58)                                        1063 (89)                               
  **Family history of prostate cancer^a^**                                                                                                        
  No                                                      498 (43)                                        796 (66.5)                              
  Yes                                                     263 (23)                                        94 (8)                                  *P* \> 0.9^d^
  Unknown                                                 392 (34)                                        306 (26)                                
  **Vasectomy status^b^**                                                                                                                         
  No                                                      286 (25)                                        699 (58)                                
  Yes                                                     148 (13)                                        445 (37)                                *P* \> 0.9^d^
  Unknown                                                 718 (62)                                        52 (4)                                  
  **Smoking status**                                                                                                                              
  Never smoked                                            426 (37)                                        496 (41)                                
  Former smoker                                           582 (50.5)                                      580 (48.5)                              *P* \> 0.9^c^
  Current smoker                                          78 (7)                                          83 (7)                                  
  Unknown                                                 67 (6)                                          37 (3)                                  
  **Alcohol consumption^b^**                                                                                                                      
  Non-drinker                                             63 (5.5)                                        143 (12)                                *P* \> 0.9^d^
  Drinker                                                 370 (32)                                        1015 (85)                               
  Unknown                                                 719 (62)                                        38 (3)                                  
  **Highest education level achieved**                                                                                                            
  No formal education                                     10 (1)                                          15 (1)                                  
  Primary/Secondary school                                516 (45)                                        469 (39)                                *P* \> 0.9^c^
  Professional qualification                              351 (30)                                        372 (31)                                
  University degree                                       211 (18)                                        304 (25)                                
  Unknown                                                 62 (5)                                          37 (3)                                  
  **Gleason score (Gleason grade 1 + Gleason grade 2)**                                                                                           
  \<7                                                     198 (17)                                        Not applicable                          
  ≥7                                                      785 (68)                                        Not applicable                          
  Unknown                                                 171 (15)                                        Not applicable                          

a

positive family history is defined as at least one first degree relative with prostate cancer.

b

data was not collected for the retrospective study.

c

P-values are from non-Parametric t-tests.

d

Two-way ANOVA tests. body mass index (BMI) calculated as: kg/m

2

.

Genomic DNA Extraction and STR Genotyping
-----------------------------------------

White blood cells were obtained from 10 ml of venous blood that were collected in EDTA tubes. Buffy coat was separated within 24 h and stored at -20°C until further processing. Genomic DNA was extracted from the buffy coats using the QIAamp DNA Mini Kit as per the manufacturer's instructions (Qiagen, Hilden, Germany) as described previously ([@B6]; [@B31]) and a multiplex PCR was performed in a 96 well plates. Briefly, the multiplex PCR kit (QIAGEN, Chadstone, VIC, Australia) was used in a 40 cycles' PCR following the manufacturer's guidelines. NED-fluorescently labeled primers (forward: 5′-GAGAAATGGCACAAAAACAGG-3′ and reverse: 5′-TTCTGTCAAGGTAATATTGCCAA-3′) were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia). The primers were designed to amplify the STRs' region at chromosome 8:126450287--126450311 position with a predicted product length of 299 bp (according to UCSC hg19). A total of thirty-one 96 well plates were subsequently analyzed according to their fragment sizes by capillary electrophoresis using the 3500 Genetic Analyzer platform (Applied Biosystems). Every plate had a well with water as a blank to determine the specificity of our PCR product and a total of 175 technical replicates were included across the plates to determine the reproducibility of the results. Technical replicates had to match in at least 90% of the hits detected to confirm the robustness of the assay. Due to the nature of the amplified and genotyped product, a 10% failure was allowed for potential mistakes at the PCR and/or genotypic levels. The results were then analyzed with GeneMapper v.5.0 (Thermo Fisher Scientific, Waltham, MA, United States).

TTTTG-*TRIB1* RT-qPCR
---------------------

The APCB prostate tumor bank provided formalin fixed and paraffin embedded (FFPE) blocks of prostate tissue, which contained both prostate tumor and adjacent non-tumor cells. The blocks were then sectioned sequentially in 20 μm sections and placed on glass slides which were methyl green stained. The pathologist marked tumor areas with their respective Gleason scores (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**). mRNA was isolated using the RNeasy FFPE Kit (QIAGEN, Chadstone, VIC, Australia), mRNA was reversed transcribed (RT) using Superscript III (Life Technologies, Scoresby, VIC, Australia) as previously described ([@B27]). RNA purity and quantity were analyzed using the nanodrop^TM^ 2000/2000c Spectrophotometers and quantitative PCR (RT-qPCR) was performed using the SYBR Green method (Life Technologies, Scoresby, VIC, Australia). Twenty available patients' tumor and adjacent non-tumor prostate tissue were selected based on their genotype as follows: 3/3 repeats (*n* = 2), 3/4 repeats (*n* = 8), and 4/4 repeats (*n* = 10). Their Gleason grades are detailed in **Supplementary Table [1](#SM1){ref-type="supplementary-material"}**. The sequence at chr8:126450219-126450357 (UCSC hg19) was amplified with a predicted PCR product length of 139 bp using the forward, 5′-GAATGCCGTGTATACCTCACG-3′, and reverse, 5′-CGCAGGTTATTCAGACAGACA-3′ primers set. Applying the geometrical mean (geomean) of multiple housekeeping genes in RT-qPCR assists in removing non-specific gene variation expression, minimizing differences in the samples gene expression detection due to variables such as the RNA quantity and quality ([@B52]). We therefore used geomean of the two control genes as reference, HPRT1 and RPL32. We then proceeded to evaluate the STR expression by calculating the ΔCT values = Ct TRIB1 -- Ct Geomean of HPRT1 and RPL32.

Statistical Analysis
--------------------

After checking if age and body mass index (BMI) followed a Gaussian distribution, they were analyzed using a non-parametric, unpaired *t*-test (GraphPad Prism 7.00). For other parameters such as smoking, drinking, and marital status, their frequencies in both cases and controls were calculated and analyzed using a paired, non-parametric *t*-test. For those parameters where only two pairs of values were available such as family history, alcohol consumption and vasectomy status, a two-way ANOVA test was used. To test if the STR was within Hardy--Weinberg equilibrium (HWE), a chi-square test with a confidence level of 0.05 was used ([@B24]). STR genotype and allele association with prostate cancer risk and aggressiveness analysis were performed using binary logistic regression and the odds ratios (ORs) were estimated as follows. For the allele analysis, the dependent variable was the prostate cancer status and the categorical covariate was the allele. In this analysis no reference was used as the covariate variable was either presence/absence of the allele (equal to 1 or 0, respectively). For the genotype analysis, the dependent variable was the prostate cancer status and the covariate variable was the genotypes. In here, the analysis used the major allele (4/4) as the reference. To verify that age was not biasing the results, a re-analysis was performed using the allele/genotype as the categorical covariate again, age as the second covariate and case-control status or Gleason score as the dependent variables. All tests were repeated using random sampling with replacement by bootstrapping analysis. The tests were seeded 1,000,000 times in 1,000 samples. Next, we analyzed the association of TTTTG*-TRIB1* STR with prostate cancer aggressiveness. A Gleason score of 8 and above is associated with a poorly differentiated or high-grade disease ([@B3]). We then grouped patients with a Gleason score of less than 8 and equal or greater than 8. Furthermore, since it has also been reported that the Gleason score pattern for a Gleason score of 7 can be an informative prognostic tool ([@B48]), where a higher primary Gleason score predicts a more lethal form of the disease, we then subdivided into 3+4 and 4+3 patients with a Gleason score = 7. Survival analysis was undertaken using the Kaplan Meier test \[Log-Rank (Mantel-Cox)\]. Data was plotted using GraphPad Prism 7.00. Hazard ratios (HR) were calculated using the Cox-Regression analysis for both total and prostate cancer related mortality. In this case the analysis was adjusted for age, Gleason score and PSA values. All analyses were conducted using IBM SPSS Statistics; 23.0 unless stated otherwise.

Differential *TRIB1* expression in prostate cancer tissue and adjacent normal tissue and correlation of genotype and allele data with STR mRNA levels were analyzed using the non-parametric Mann--Whitney test and plotted using GraphPad Prism 7.00. A two tailed *P* \< 0.05 value was considered significant for all the analysis.

TTTTG-*TRIB1* mRNA Structure Prediction
---------------------------------------

In order to assess the potential impact that the two most common alleles of TTTTG-*TRIB1* have on the TRIB1 mRNA folding structure, the *in silico* RNA folding predictor tool, mfold web server v.3^[1](#fn01){ref-type="fn"}^, was used ([@B65]). There are two transcript variants of TRIB1 according to the RefSeq genes data set: transcript variant 1, NM_025195.3, and transcript variant 2, NM_025195.1. Both were analyzed with the two most common alleles, three- and four-TTTTG-*TRIB1* repeats. Since mfold calculates the most energetic favorable secondary structures that compose a mRNA molecule (given by their minimum free energy thermodynamic parameter, ΔG°), we hypothesized that the alleles may have an effect in the final folded structure and, potentially, in the final stability of the molecule, affecting the functionality and/or levels of the translated protein.

The Ingenuity Pathway Analysis (IPA; QIAGEN, Redwood City, CA, United States) was used to identify a list of miRNAs that bind to *TRIB1* and are deregulated in prostate cancer. From these, we sought for further confirmation in the miRNet database ([@B16]). Next, microRNA.org was used to find predicted miRNAs to bind near the STR ([@B8]). Finally, RNAhybrid ([@B39]) was applied to detect if the miRNAs' seed region of any of these miRNAs was altered by the allele change.

Results
=======

*TRIB1* Is Highly Expressed in Prostate Cancer
----------------------------------------------

Oncomine analysis ([www.oncomine.org](http://www.oncomine.org) ([@B40])) revealed *TRIB1* is highly expressed in prostate cancer when compared to other types of cancers in two multi-cancer clinical datasets, suggesting a specific role of *TRIB1* in this particular disease. [@B49] showed an overexpression (**Figure [1A](#F1){ref-type="fig"}**) in prostate cancer tissue when compared to bladder, breast, colorectal, kidney, liver, lung, ovarian, and pancreatic cancers (*n* = 174). Additionally, [@B38] reported *TRIB1* to be overexpressed in prostate tumor tissue when compared to breast, colorectal, lung and ovarian cancer tissues (*n* = 76; **Figure [1B](#F1){ref-type="fig"}**). Furthermore, two independent data sets also showed an increase of mRNA expression in prostate cancer when compared to adjacent cancer-free tissue (**Figures [1C,D](#F1){ref-type="fig"}**; [@B30]; [@B18], respectively), which suggests that *TRIB1* may be associated with prostate cancer initiation and/or development.

Demographic and Clinical Characteristics of the Cohort
------------------------------------------------------

Epidemiological data is shown in **Table [1](#T1){ref-type="table"}**. The socio-demographic and clinical characteristics analysis showed no significant differences between cases and controls for all of the parameters analyzed (**Table [1](#T1){ref-type="table"}**). Therefore, these parameters were not used further. Only the mean of the age was significantly different between the two groups (*P* \< 0.05). This was expected due to the nature of the recruitment of some healthy controls, where samples from random blood donors were collected and some were younger participants than the patient cohort.

The TTTTG*-TRIB1* STR Is Associated With Prostate Cancer Risk but Not With Aggressiveness
-----------------------------------------------------------------------------------------

In some instances, one of the technical replicates failed, either due to amplification and/or electrophoresis issues. Of the genotyped duplicates, 92% showed concordant results, satisfying the quality control criteria of STR genotyping. We then proceed to analyze our STR genotyping results. Three alleles were observed for the TTTTG-*TRIB1* STR, varying from three- to five-repeats. All alleles were in HWE (*P* = 0.51). The three-repeat allele was associated with prostate cancer risk at the allelic (OR = 1.16; 95%; CI = 1--1.34; *P* = 0.044) and genotypic levels (OR = 1.70; 95% CI = 1.16--2.49; *P* = 0.006; **Table [2](#T2){ref-type="table"}**). The four-repeat allele inversely associated with risk of prostate cancer at the allele level (OR = 0.57; 95% CI = 0.44--0.75; *P* \< 0.0001; **Table [2](#T2){ref-type="table"}**). Similar results were obtained after age adjusting and bootstrap reanalysis (**Table [2](#T2){ref-type="table"}**). The rest of the genotypes (3/5, 4/5, and 5/5) were not analyzed due to the low number of observations (\<1%).

###### 

Allele and genotype risk association analysis of TTTTG*-TRIB1* STR with prostate cancer risk.

  Genotype     Cases (%)   Controls (%)   OR (95%CI)^a^       *P*-value^a^   OR (95% CI)^b^      *P*-value^b^   *P*-value^c^   *P*-value^d^
  ------------ ----------- -------------- ------------------- -------------- ------------------- -------------- -------------- --------------
  3/3          74 (6)      47 (4)         1.70 (1.16--2.49)   0.006          1.65 (1.12--2.44)   0.011          0.006          0.01
  3/4          365 (32)    384 (31)       1.03 (0.86--1.23)   0.75           --                  --             --             --
  3/5          1 (0.1)     0              --                  --             --                  --             --             --
  4/4          701 (61)    759 (63)       1                                  --                  --             --             --
  4/5          9 (0.7)     9 (0.7)        --                  --             --                  --             --             --
  5/5          2 (0.2)     0              --                  --             --                  --             --             --
  **Allele**                                                                                                                   
  3            514 (22)    478 (20)       1.16 (1.00--1.34)   0.044          1.18 (1.01--1.36)   0.03           0.044          0.031
  4            1776 (77)   1911 (80)      0.57 (0.44--0.75)   \<0.0001       0.59 (0.45--0.77)   \<0.0001       0.001          0.001
  5            14 (0.6)    9 (0.4)        --                  --             --                  --             --             --

Calculated using

a

binary Logistic Regression, where the dependant variable is the case-control status and the covariate is the allele/genotype

b

age adjusted binary logistic regression, where age is the second covariate

c

bootstrap (two-tailed) and

d

bootstrap (two-tailed) age adjusted. (IBM SPSS Statistic Processor; 23). CI, confidence interval; OR, odds ratio.

No significant association betweeen the genotypes and Gleason scores was obseved (*P* \> 0.05; **Supplementary Table [2](#SM2){ref-type="supplementary-material"}**), suggesting the TTTTG-*TRIB1* STR alleles have no effect in the disease's aggressiveness.

A total of 67 deaths were reported from the total cohort of 1,152 patients, of which 25 were prostate cancer-related. No significant differences in mortality were observed between the 3/3, 3/4, and 4/4 TTTTG-*TRIB1* genotypes etiher for total mortality data \[Log-Rank(Mantel-Cox) *P* = 0.695; **Figure [2A](#F2){ref-type="fig"}**\] or prostate cancer related deaths \[Log-Rank (Mantel-Cox) *P* = 0.466; **Figure [2B](#F2){ref-type="fig"}**\] and these results were not affected by age, Gleason scores and PSA values (HR and their respective *P*-values are in **Figure [2](#F2){ref-type="fig"}**). Those patients with 5 TTTTG-*TRIB1* repeats (3/5, 4/5, and 5/5) were not included in the analysis due to their low incidence (*n* = 1, 3 and 7, respectively).

![Survival data analysis. **(A)** Total mortality data \[Log-Rank (Mantel-Cox) *P*-value = 0.16\], **(B)** prostate cancer mortality data \[Log-Rank (Mantel-Cox) *P*-value = 0.43\] where TTTTG-*TRIB1* genotypes (3/3, 3/4, 4/4) are represented as a function of percentage survival over 125 months. HR and *P*-values were calculated using Cox-Regression analysis and adjusted for age, Gleason score and PSA values. HR, hazard ratio; CI, confidence interval.](fgene-09-00428-g002){#F2}

*TRIB1* mRNA Expression Is Not Associated With the STR Allele
-------------------------------------------------------------

The *TRIB1* gene expression showed a higher expression in prostate cancer tumor when compared to adjacent non-malignant tissue (*P* = 0.0005; **Figure [3A](#F3){ref-type="fig"}**). To identify if the STR alleles regulate *TR1BI* expression in tumor tissue, we analyzed the patient's RNA from genotype two groups, i.e., carrying the three repeats allele or carrying the four repeats allele. No allele and TR1B1 mRNA expression correlation was observed either in the tumor (**Figure [3B](#F3){ref-type="fig"}**) or in the adjacent benign tissue (**Figure [3C](#F3){ref-type="fig"}**).

![RT-qPCR from twenty patient tissue samples for TTTTG-*TRIB1*. Expression of the **(A)** *TRIB1* gene in tumor tissues when compared to adjacent non-malignant tissues and expression of the 3- and 4-repeats alleles in **(B)** tumor tissues and **(C)** adjacent non-malignant tissues. ^∗∗∗^*P* = 0.0005, value calculated using the Mann--Whitney test (GraphPad Prism 7.00).](fgene-09-00428-g003){#F3}

TTTTG-*TRIB1* Alleles May Alter the mRNA Secondary Structure
------------------------------------------------------------

From the 45--50 mRNA folded structures predicted by the *in silico* mfold tool, we focused on the top ten most energetically favorable ones, and compared how the change from three- to four-TTTTG repeats affected the structures of the two TRIB1 transcripts mentioned before. Four mRNA structures from the top ten were different as a consequence of the allelic change in the TRIB1 transcript variant 1 (NM_025195.3; example shown in **Figures [4A,B](#F4){ref-type="fig"}**). When the TRIB1 transcript variant 2 (NM_025195.1) was analyzed, there were eight mRNA predicted structures from the top ten that were different as a consequence of the allelic modification, including the most favorable structure (**Figures [4C,D](#F4){ref-type="fig"}**). This suggests the TTTTG-*TRIB1* alleles influence the mRNA folding structure and potentially this could also have an impact in the expression of the translated protein, which could explain the differences in prostate cancer risk observed in this study.

![Predicted secondary structures of the two *TRIB1* mRNA transcripts. Showing two examples of the differences observed in the predicted TRIB1 mRNA structure of the *TRIB1* transcript variant one with the three **(A)** and four **(B)** TTTTG-*TRIB1* repeats alleles; and of the *TRIB1* transcript variant two with the three **(C)** and four **(D)** TTTTG-*TRIB1* repeats alleles. The dotted squares highlight the secondary structures differences in the final structure. Data obtained from mfold web server v.3 (<http://www.bioinfo.rpi.edu/applications/mfold>.).](fgene-09-00428-g004){#F4}

Since the TTTTG-*TRIB1* STR is within the 3′UTR, we investigated if the alleles have an effect in regulating the *TRIB1* gene expression by affecting the miRNA binding site region and interfering in the miRNA--mRNA duplex formation. The alleles of the TTTTG-*TRIB1* STR were not predicted to have an effect on any of the analyzed miRNAs binding.

Discussion
==========

Short tandem repeats are attractive biomarkers in human disease due to their highly polymorphic nature, abundancy and wide distribution throughout the genome ([@B43]; [@B59]). They have been used for linkage mapping in several organisms, including humans ([@B56]) and they have been associated with genetically simple and complex human diseases ([@B22]; [@B59]), including neurological disorders ([@B9]). A recent publication has shown massive STR sequencing (STR-Seq) is possible using the CRISPR-Cas9 technology ([@B45]). This study, published after our analysis was done, not only highlights the power of STRs as tools for genetic diagnosis, but it also shows the on-going interest of pursuing the sequencing of STRs for genetic association studies. However, this novel STR-Seq approach may not always be suitable to implement as it may depend on the resources available. In this study, we used a pre-screening approach where existing databases and bioinformatics tools were applied to detect STRs within differentially expressed genes in prostate cancer as shown in our recent publication ([@B27]). Using such methodology, we identified a penta-STR within the 3′UTR of the *TRIB1* gene: TTTTG. This gene is part of the tribbles family, comprised of three genes: *TRIB1*, *TRIB2*, and *TRIB3*. It is a highly conserved pseudokinase ([@B62]) that lacks the protein-to-protein interaction domains and possibly any catalytic activity ([@B55]). Instead of directly phosphorylating proteins, this family of genes acts as an adaptor protein that regulates several cell pathways by enabling the degradation of targeted proteins after interacting with different cell mediators ([@B55]; [@B12]). Intracellularly, *TRIB1* has an important role of regulating the C/EBP family of transcription factors ([@B62]), responsible of processes such as transcription/translation and isoform formation ([@B21]). *TRIB1* is also a known regulator of the mitogen-activated protein kinase (MAPK) pathway ([@B50]; [@B62]), which activates/inhibits key cell processes such as growth, proliferation, differentiation, migration, and apoptosis, all of which have a pivotal role in cancer development and progression ([@B11]; [@B41]). In fact, *TRIB1* has been described as a myeloid oncogene due to its strong link with leukemia ([@B42]; [@B62]). In a previously mentioned recent study, the *TRIB1* gene has also shown to play a significant role in prostate cancer, where its knockdown decreased the proliferation and survival of prostate cancer cells in a three-dimensional *in vitro* model, as well as it promoted prostate tumorigenesis in an *in vivo* xenograft model after gene over-expression ([@B32]). The increase in prostate tumor growth observed was reversed in a *TRIB1* knockdown model. In addition, *TRIB1* has also been shown to be downregulated by androgens in LNCaP prostate cancer cells ([@B35]; [@B27]). Since androgens are a key signaling molecule in prostate cancer development and the main current therapeutic target (androgen deprivation therapy), this suggests *TRIB1* plays a role in the onset and/or development of the disease. It is not surprising then that the publicly available database Oncomine ([@B40]), revealed numerous independent clinical datasets that showed an overexpression of this gene in prostate cancer tissue when compared to adjacent cancer-free cells ([@B28]; [@B53]; [@B30]; [@B51]; [@B18]). Interestingly, Oncomine analysis also showed that *TRIB1* is highly expressed in prostate cancer when compared to other types of cancers in two independent multi-cancer studies ([@B49]; [@B38], respectively). All this evidence supports a role of *TRIB1* in the onset and/or progression of the disease.

In this study, we genotyped over 2,000 patients and matching controls for the TTTTG-*TRIB1* STR and found three alleles (three, four, and five repeats) in this population. The three-repeat allele showed a prostate cancer risk association at both the allele (*P* = 0.044) and genotype levels (*P* = 0.006) and this was stronger in the genotype analysis (OR = 1.16 vs. OR = 1.70). This difference could be due to a synergistic effect of the two alleles when combined. This study also showed that the allele/genotype does not affect the disease aggressiveness. Both results showed not to be associated with age after being age-adjusted. Additionally, no association with prostate cancer survival was observed, possibly due to the low number of reported deaths in our data set. Further follow ups, where more prostate cancer related deaths may be reported, could elucidate the role of this STR as a prognostic tool if such role indeed exists. We did not observe age, Gleason score or PSA had an effect on survival analysis in our cohort despite Gleason scores have previously shown to influence the prognosis of prostate cancer patients ([@B60]). Although not significant, an opposite effect of the 4/4 genotype with survival compared to its risk association with prostate cancer was observed. This could be due to the context dependent function of these alleles in the tumor microenvironment of an aggressive cancer vs. less aggressive tumor conditions, which has also been reported in recent publications such as SNP association studies ([@B58]; [@B36], [@B37]; [@B1]). For example, a risk allele of the MSMB gene has been reported to be associated with prostate cancer compared to controls, but its association was stronger for non-fatal prostate cancer. Furthermore, the frequency of the risk allele was higher for non-fatal prostate cancer compared with fatal prostate cancer, but it was also associated with a decreased rate of progression to prostate cancer specific mortality ([@B58]; [@B36]). [@B1], also reported that a risk allele in the MSMB and 8q24 genes were associated with an increased risk of metastatic prostate cancer compared with controls but not with time of recurrence in prostate cancer cases following diagnosis. Therefore, the observation that that the 4/4 genotype individuals have poorer survival (although not significant) and it is inversely associated with risk of prostate cancer is not surprising. Another limitation of this study was that our access to prostate tumor tissue and their adjacent non-tumor cells was limited in number: *n* = 10 for the three-TTTTG repeats and *n* = 18 for the four-TTTTG repeats allele, and therefore the results should be read with caution. This could explain why no significant differences in allele specific mRNA expression were observed. Future analysis, where additional samples can be included may clarify if the *TRIB1* expression in prostate tumor tissue contributes to a poorer survival outcome as recently shown in a breast cancer study ([@B17]).

Since this STR is in the 3′UTR and its two most common alleles, three- and four-TTTTG repeats, have a difference of five nucleotides, we hypothesized this could affect either the miRNAs binding site or the final mRNA folding, and therefore have an effect in the stability and translation of the protein, potentially affecting the TRIB1 protein levels. Our miRNA analysis showed no differences in the 3′ UTR seed region when changing the STR allele from three- to four-repeats, suggesting the risk differences observed in this study are due to other regulatory mechanisms. Alternatively, there could be one or more miRNAs not yet identified that are affected by the polymorphism of the STR. We then focused on how the alleles could affect the TRIB1 mRNA structure. The predictor tool, mfold v3.0, showed the TTTTG-*TRIB1* alleles altered not only the order in which a given structure was most favorable but they also promoted unique structures for the two known TRIB1 transcripts. It would be interesting to investigate further the role of these two transcripts in prostate cancer development and if the TTTTG-*TRIB1* STR found herein has indeed an effect on TRIB1 mRNA stability, by possibly promoting or interfering in the translation of the mRNA. However, it is important to note that the minimum free energy method used by the mfold predictor tool has its own limitations such as assuming the RNA molecule is in equilibrium, that it has a single conformation and the nearest-neighbor effects are non-existent ([@B33]). For these reasons, additional computational methods should be used to confirm the physiological significance of these findings and they also need to be experimentally validated by analyzing the allele specific protein expression of the *TR1BI* with a recently validated antibody ([@B46]). Finally, although we identified the TR1B1 STR through a method completely independent of GWAS, and for the first time analyzed the association of a polymorphism within the *TRIB1* gene, it must be mentioned that several SNPs associated with prostate cancer have been detected by GWAS in the same locus than the *TRIB1* gene ([@B20], [@B19]; [@B47]). It would therefore be imperative to establish the TR1B1 STR as an independent marker to GWAS identified SNPs at 8q24 for prostate cancer by undertaking the regression analysis conditioned on the GWAS loci.

In summary, the *TRIB1* gene is significantly overexpressed in prostate cancer when compared to other types of cancer and it is upregulated in prostate tumor tissue when compared to adjacent cancer-free cells. After genotyping over 2,000 prostate cancer patients and controls, we found the TTTTG-*TRIB1* STR is polymorphic and its three repeats allele has an association with prostate cancer risk at both the allelic and genotypic levels. However, no associations with mortality or aggressive disease were found. Further association studies in a larger cohort are warranted to confirm the outcome of our study. Our *in silico* predictions indicated that the TRIB1 mRNA structures are allele dependent. This repeat length could be affecting the mRNA stability and hence their expression level. Additional mechanisms by which this STR regulates *TRIB1* expression in an allele specific manner need to be further explored. Collectively, these findings validate our biomarker discovery approach methodology and highlight the utility of pursuing the use of STRs as biomarkers.
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